<?xml version="1.0" encoding="UTF-8"?>
<ref id="B6-pharmaceutics-11-00231" class="ref">
 <label class="label">6.</label>
 <element-citation publication-type="journal" class="element-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Pfaller</surname>
    <given-names class="given-names">M.A.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Messer</surname>
    <given-names class="given-names">S.A.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Woosley</surname>
    <given-names class="given-names">L.N.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Jones</surname>
    <given-names class="given-names">R.N.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Castanheira</surname>
    <given-names class="given-names">M.</given-names>
   </name>
  </person-group>
  <article-title class="article-title">Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New Clsi Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance</article-title>
  <source class="source">J. Clin. Microbiol.</source>
  <year class="year">2013</year>
  <volume class="volume">51</volume>
  <fpage class="fpage">2571</fpage>
  <lpage class="lpage">2581</lpage>
  <pub-id pub-id-type="doi" class="pub-id">10.1128/JCM.00308-13</pub-id>
  <?supplied-pmid 23720791?>
  <pub-id pub-id-type="pmid" class="pub-id">23720791</pub-id>
 </element-citation>
</ref>
